Roche’s Tecentriq Extends Lung-Cancer Patients’ Lives in Study

Lung-cancer patients who took Roche Holding AG’s new medicine Tecentriq lived about four months longer than those on chemotherapy in a study that will help position the drug to compete in the increasingly crowded field of immunotherapy. 

To continue reading this article you must be a Bloomberg Professional Service Subscriber.